Literature DB >> 20447940

Pulmonary hypertension: advances in pathogenesis and treatment.

M Toshner1, T Tajsic, N W Morrell.   

Abstract

Pulmonary hypertension is an orphan disease that until recently has received limited attention within the wider medical community. This has changed distinctly in the last 10 years with the advent of new classes of therapy and a renewed interest in mechanisms of pathogenesis. This review utilized information gathered from recent conferences, and a review of the literature was conducted using MedLine and Pubmed. Accepted mechanisms of pathogenesis and currently available treatments are presented. We will discuss interesting new concepts in pathogenesis, including the importance of genetic forms of the disease and in particular the transforming growth factor receptor superfamily and the evolving evidence of the contribution of dysregulated immunity. Areas of research may yield therapeutic benefits in the not-too-distant future, including anti-proliferative therapies and stem cell therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20447940     DOI: 10.1093/bmb/ldq012

Source DB:  PubMed          Journal:  Br Med Bull        ISSN: 0007-1420            Impact factor:   4.291


  8 in total

1.  [Histopathological aspects of pulmonary hypertension].

Authors:  D Jonigk; M M Hoeper; H Kreipe; F Länger
Journal:  Pathologe       Date:  2012-05       Impact factor: 1.011

2.  Peroxisome proliferator-activated receptor-γ enhances human pulmonary artery smooth muscle cell apoptosis through microRNA-21 and programmed cell death 4.

Authors:  David E Green; Tamara C Murphy; Bum-Yong Kang; Brahmchetna Bedi; Zhihong Yuan; Ruxana T Sadikot; C Michael Hart
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-05-18       Impact factor: 5.464

3.  Bone morphogenetic protein signaling in vascular disease: anti-inflammatory action through myocardin-related transcription factor A.

Authors:  Dahai Wang; Jamunabai Prakash; Peter Nguyen; Brandi N Davis-Dusenbery; Nicholas S Hill; Matthew D Layne; Akiko Hata; Giorgio Lagna
Journal:  J Biol Chem       Date:  2012-06-20       Impact factor: 5.157

Review 4.  Scleroderma lung disease.

Authors:  Joshua J Solomon; Amy L Olson; Aryeh Fischer; Todd Bull; Kevin K Brown; Ganesh Raghu
Journal:  Eur Respir Rev       Date:  2013-03-01

5.  Collagen Metabolism Biomarkers and Health Related Quality of Life in Pulmonary Arterial Hypertension.

Authors:  Zeenat Safdar; Emilio Tamez; Adaani Frost; Danielle Guffey; Charles G Minard; Mark L Entman
Journal:  Int J Cardiovasc Res       Date:  2015

6.  Beta-estradiol attenuates hypoxic pulmonary hypertension by stabilizing the expression of p27kip1 in rats.

Authors:  Dun-Quan Xu; Ying Luo; Yi Liu; Jing Wang; Bo Zhang; Min Xu; Yan-Xia Wang; Hai-Ying Dong; Ming-Qing Dong; Peng-Tao Zhao; Wen Niu; Man-Ling Liu; Yu-Qi Gao; Zhi-Chao Li
Journal:  Respir Res       Date:  2010-12-24

Review 7.  Apelin, Elabela/Toddler, and biased agonists as novel therapeutic agents in the cardiovascular system.

Authors:  Peiran Yang; Janet J Maguire; Anthony P Davenport
Journal:  Trends Pharmacol Sci       Date:  2015-07-01       Impact factor: 14.819

8.  Clinical trial protocol for TRANSFORM-UK: A therapeutic open-label study of tocilizumab in the treatment of pulmonary arterial hypertension.

Authors:  Jules Hernández-Sánchez; Louise Harlow; Colin Church; Sean Gaine; Emily Knightbridge; Kate Bunclark; Dee Gor; Alun Bedding; Nicholas Morrell; Paul Corris; Mark Toshner
Journal:  Pulm Circ       Date:  2017-09-28       Impact factor: 3.017

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.